Activists are fighting for the availability of PrEP in Russia
25 Russian public organizations have signed an open letter to the biopharmaceutical company Gilead, in which they ask the developer of Truvada to give up patent rights to PreP in Russia. Currently, the combination of two antiretroviral drugs (tenofovir and emtricitabine), registered under the trade name Truvada, is protected by a patent, which allows Gilead to remain a monopolist in the Russian market.